Bristol Vanlev OCTAVE Data: Angioedema Risk Suggests Second-Line Use
Executive Summary
Bristol-Myers Squibb's Vanlev OCTAVE data suggest that the review of the antihypertensive candidate will focus on a potential second-line indication to the ACE inhibitor enalapril